Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion (EGP_Glucagon)

University Hospital, Gentofte, Copenhagen

Status

Completed

Conditions

Type 2 Diabetes Mellitus

Treatments

Biological: isoglycemic intravenous glucose infusion and Glucagon infusion, day C

Biological: intravenous iv glucose infusion, day B

Biological: Oral glucose tolerance test, day A

Study type

Observational

Funder types

Other

Identifiers

NCT02010827

H-4-2013-012

Details and patient eligibility

About

We want to investigate how lack of glucagon suppression during an oral glucose tolerance test in patients with type 2 diabetes contributes to patients postprandial hyperglycemia.

Full description

Patients with type 2 diabetes mellitus (T2DM) are not able to suppress their glucagon secretion after a meal or after ingestion of glucose. Previous studies have shown that gastrointestinal hormones might play a role in this phenomenon. However, it has not yet been possible to determine whether this lack of glucagon suppression postprandially results in an increased endogenous glucose secretion, and thus is a factor in the patients postprandial hyperglycemia.

We aim to perform oral glucose tolerance tests and isoglycemic intravenous glucose infusions with and without a continuous glucagon infusion in patients with T2DM and healthy control subjects. The glucagon infusion is aiming at copying the inappropriate "physiological" glucagon response observed in patients with T2DM.

Enrollment

20 patients

Sex

All

Ages

35 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patients with T2DM

Caucasions above 35 years of age with diet and/or tablettreated T2DM of at -least three months (diagnosis acording to WHO)
Normal haemoglobin
Informed consent

Healthy Subjects

Normal fasting plasma glucose (FPG) and normal HbA1C (according to the -World Health Organization (WHO) criteria)
Normal haemoglobin
Age above 35 years
Informed consent

Exclusion criteria

Inflammatory bowel disease
Nephropathy (serum creatinine >150 µM and/or albuminuria)
Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) >3×normal values)
Pregnancy and/or breastfeeding
Age above 80 years
Any condition that the investigator feels would interfere with trial participation

Patients with T2DM

Healthy Subjects

Diabetes mellitus (DM)
Prediabetes (impaired glucose tolerance and/or impaired FPG)
First degree relatives with DM
Inflammatory bowel disease
Intestinal resection and/or ostomy
Nephropathy (serum creatinine >150 µM and/or albuminuria
Liver disease (ALAT and/or serum ASAT >2×normal values)
Pregnancy and/or breastfeeding
Age above 80 years
Any condition that the investigator feels would interfere with trial participation